BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23344201)

  • 21. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
    Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
    J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
    Ouellet E; Ayan D; Poirier D
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency.
    Boutin S; Maltais R; Roy J; Poirier D
    Eur J Med Chem; 2021 Jan; 209():112909. PubMed ID: 33081987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemical synthesis and biological activities of 16alpha-derivatives of 5alpha-androstane-3alpha,17beta-diol as antiandrogens.
    Roy J; Breton R; Martel C; Labrie F; Poirier D
    Bioorg Med Chem; 2007 Apr; 15(8):3003-18. PubMed ID: 17336533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
    Laplante Y; Poirier D
    Steroids; 2008 Mar; 73(3):266-71. PubMed ID: 18082864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parallel solid-phase synthesis of 3beta-peptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of type 3 17beta-hydroxysteroid dehydrogenase.
    Maltais R; Luu-The V; Poirier D
    Bioorg Med Chem; 2001 Dec; 9(12):3101-11. PubMed ID: 11711285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
    Byrns MC; Mindnich R; Duan L; Penning TM
    J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
    Bérubé M; Poirier D
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
    Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
    Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preselection of A- and B- modified d-homo lactone and d-seco androstane derivatives as potent compounds with antiproliferative activity against breast and prostate cancer cells - QSAR approach and molecular docking analysis.
    Kovačević SZ; Podunavac-Kuzmanović SO; Jevrić LR; Vukić VR; Savić MP; Djurendić EA
    Eur J Pharm Sci; 2016 Oct; 93():107-13. PubMed ID: 27503457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
    Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
    Day JM; Tutill HJ; Purohit A; Reed MJ
    Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
    Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
    Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of steroidogenesis and steroidogenic enzyme functions.
    Luu-The V
    J Steroid Biochem Mol Biol; 2013 Sep; 137():176-82. PubMed ID: 23770321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
    Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
    Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
    Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
    J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
    Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
    J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.